Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 12:41PM ET
2.88
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-1.59 Insider Own39.80% Shs Outstand65.47M Perf Week3.60%
Market Cap188.55M Forward P/E- EPS next Y-0.61 Insider Trans-0.10% Shs Float39.41M Perf Month93.29%
Income-30.04M PEG- EPS next Q-0.22 Inst Own23.55% Short Float13.02% Perf Quarter119.85%
Sales0.00M P/S- EPS this Y67.88% Inst Trans6.47% Short Ratio1.70 Perf Half Y111.76%
Book/sh1.05 P/B2.75 EPS next Y-20.20% ROA-77.55% Short Interest5.13M Perf Year246.78%
Cash/sh0.36 P/C7.91 EPS next 5Y39.60% ROE-110.27% 52W Range0.77 - 3.79 Perf YTD125.00%
Dividend Est.- P/FCF- EPS past 5Y50.96% ROI-135.05% 52W High-24.01% Beta1.55
Dividend TTM- Quick Ratio2.96 Sales past 5Y1867.07% Gross Margin- 52W Low274.03% ATR (14)0.31
Dividend Ex-Date- Current Ratio2.96 EPS Y/Y TTM14.84% Oper. Margin0.00% RSI (14)75.92 Volatility11.59% 16.37%
Employees30 Debt/Eq0.15 Sales Y/Y TTM- Profit Margin- Recom1.50 Target Price7.25
Option/ShortYes / Yes LT Debt/Eq0.05 EPS Q/Q1.21% Payout- Rel Volume0.21 Prev Close2.88
Sales Surprise- EPS Surprise-0.08% Sales Q/Q- EarningsMar 21 AMC Avg Volume3.02M Price2.88
SMA2036.43% SMA5072.27% SMA20097.67% Trades Volume327,384 Change0.00%
Date Action Analyst Rating Change Price Target Change
Mar-18-24Initiated Leerink Partners Outperform $6
Mar-28-18Initiated B. Riley FBR, Inc. Neutral $1
Jan-05-18Initiated Leerink Partners Outperform $2
Jun-13-17Reiterated Chardan Capital Markets Buy $5 → $2.50
Mar-06-17Reiterated Wedbush Outperform $8 → $6
Jan-30-17Downgrade Wells Fargo Outperform → Market Perform
Jan-30-17Downgrade Needham Buy → Hold
Dec-07-16Reiterated Chardan Capital Markets Buy $12 → $5
Nov-02-16Reiterated Needham Buy $10 → $9
Jul-25-16Reiterated Chardan Capital Markets Buy $14.50 → $12
Mar-23-24 05:33AM
Mar-21-24 10:53PM
04:22PM
04:05PM
Mar-13-24 12:09PM
06:32AM Loading…
Mar-12-24 06:32AM
06:30AM
Jan-02-24 04:05PM
Nov-22-23 08:00AM
Nov-09-23 04:32PM
04:05PM
Nov-02-23 08:00AM
Oct-19-23 08:00AM
Sep-20-23 07:00AM
Sep-13-23 08:00AM
08:00AM Loading…
Sep-05-23 08:00AM
Aug-24-23 07:33PM
Aug-23-23 01:04PM
08:00AM
Aug-08-23 04:43PM
04:05PM
Aug-02-23 08:00AM
Jul-18-23 08:00AM
Jun-27-23 08:00AM
Jun-23-23 08:00AM
Jun-20-23 08:00AM
Jun-12-23 08:00AM
May-16-23 08:00AM
May-11-23 04:18PM
04:05PM
08:00AM Loading…
Apr-13-23 08:00AM
Apr-12-23 04:05PM
Mar-23-23 04:52PM
04:05PM
Feb-09-23 08:00AM
Jan-13-23 04:05PM
Jan-09-23 06:01AM
Dec-12-22 08:00AM
Nov-29-22 05:43PM
08:00AM
Nov-10-22 04:05PM
Nov-03-22 08:00AM
Nov-02-22 08:00AM
Sep-13-22 11:58AM
Sep-12-22 11:14AM
08:00AM
Sep-02-22 04:05PM
Aug-11-22 04:10PM
Aug-04-22 08:00AM
Jun-21-22 08:00AM
Jun-13-22 08:00AM
Jun-02-22 08:00AM
May-17-22 04:30PM
07:00AM
May-12-22 04:05PM
10:20AM
May-11-22 08:00AM
May-05-22 04:05PM
Mar-24-22 12:03PM
08:00AM
Mar-10-22 04:05PM
Mar-03-22 05:15PM
Feb-24-22 08:00AM
Feb-10-22 04:30PM
Jan-26-22 10:00AM
Jan-20-22 05:18PM
Jan-19-22 09:38AM
Jan-04-22 08:00AM
Dec-03-21 08:30AM
Dec-01-21 08:30AM
Nov-30-21 05:23PM
Nov-24-21 04:05PM
Nov-10-21 05:45PM
04:05PM
Nov-03-21 05:15PM
Oct-28-21 03:05PM
Oct-13-21 03:11PM
12:27PM
07:27AM
Oct-12-21 04:05PM
Sep-30-21 04:45PM
Sep-09-21 04:40PM
Sep-06-21 02:33PM
Aug-10-21 05:55PM
04:05PM
Aug-03-21 05:15PM
Jun-30-21 09:33AM
Jun-25-21 01:38PM
07:05AM
Jun-21-21 07:00AM
Jun-11-21 08:56AM
May-21-21 10:47AM
08:07AM
May-14-21 04:07PM
May-13-21 05:35PM
04:07PM
03:15PM
May-06-21 03:01PM
May-03-21 09:25AM
08:00AM
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hagan Joseph PChief Executive OfficerJan 18 '24Sale1.1914,58017,35957,112Jan 18 08:22 PM
CALSADA CRISPINAChief Financial OfficerJan 18 '24Sale1.195,4686,5105,782Jan 18 08:24 PM
Aker Christopher RaySr. VP & General CounselJan 18 '24Sale1.195,4686,51010,056Jan 18 08:23 PM